/
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients lives. Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harn…
The business is unprofitable at the operating level (-320.53% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue growth slowed to 1.0%, essentially flat. This is a business that needs a catalyst.
Negative free cash flow of -$99M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$35M
▲ +1.0% YoY
Net Income (TTM)
-$104M
▲ +0.3% YoY
Op. Margin
-326.56%
▲ +15.6pp YoY
ROIC
-33.87%
▲ +1.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$96M
▼ -52.0% YoY
Op. Cash Flow (TTM)
-$95M
▼ -51.5% YoY
Net Debt
-$177M
Net Cash Position
Cash & Equiv.
$236M
3Y CAGR: +5.0%
Continue Research